

Modern drug development demands speed, adaptability, and access to the right patient populations at the right time. Our multi-center clinical trial solutions give you the flexibility to launch, scale, and conduct clinical trials across Altasciences' clinical research units (CRUs), external sites, or a blend of both, while maintaining unified oversight and quality.

Choose From Our Three Models



Altasciences-only

Phase I, Ia-IIa

Healthy Volunteers and Select Patient Populations

Altasciences' CRUs are ideal for early-phase studies requiring intensive monitoring. With three early-phase clinical pharmacology units in Montréal, Los Angeles, and Kansas City, these settings support efficient study execution from the outset.

- Fast start-up timelines
- Highly controlled environment
- Ideal for SAD/MAD, PK/PD, early mechanism studies in healthy volunteers
- Ability to scale quickly as needed



Altasciences + Partner Sites, or Partner Sites Only

Clinical Pharmacology Trials

Special Populations and PK/PD Focus

Altasciences' partner sites extend geographic reach and provide access to diverse and specialty patient populations, supporting a wide range of study designs and therapeutic areas.

- Access to specialized patient populations and expanded geographic reach
- Supports food effect, drug-drug interaction, bioavailability/bioequivalence, and specialized PK/PD study designs
- Efficient scalability across multiple sites



Altasciences + Site Network, or Site Network Only

Phase Ib-IIb

Patient Cohorts and Therapeutic Area-Driven

Altasciences' site network expands beyond our proprietary CRUs and partners to support larger phase Ib to IIb trials. Our flexible, integrated site model combines our proprietary CRUs with a broad network of 500+ qualified investigational sites across North America and enables scalable and seamless execution across early- and mid-phase studies.

- Expertise in CNS, GI, metabolic, ophthalmic, and dermatologic therapeutic areas
- Flexible study execution including Altasciences' CRUs, site network, or both
- Centralized oversight across all sites
- Full-service site management from selection through close-out

What Sets Altasciences Apart

One Program. One Team. Zero Silos.

- End-to-end integration from FIH to Phase IIb
- Faster study start-up and time to data
- Broader patient access
- One program lead
- Consistent SOPs and workflows
- Real-time data visibility

Connecting the Right Participants to Your Trial

We provide access to a broad range of patient populations, enabling trials designed around scientific need—not by population limitation—to keep your molecule moving forward.

- CNS disorders
- Metabolic dysfunction (MAFLD/MASH)
- Hepatic/Renal impairment
- Ophthalmology and dermatology
- Geriatric, ethnobridging, genotyped volunteers
- Cardiometabolic
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Obesity
- Pain

Faster by Design

Whether you need accelerated proof-of-concept, broader patient access, geographic diversity, or expansion beyond single-site limitations, Altasciences helps you reach value-inflection points sooner, without compromising scientific excellence or quality.



Strategic Site Identification and Feasibility

Our experts bring over a decade of experience managing multi-center programs. All external sites undergo rigorous qualification to ensure infrastructure, staffing, and compliance readiness. Our established relationships with on-boarded sites enable rapid site activation and accelerated feasibility.

The feasibility process includes:

- Early study engagement during proposal development
- Customized questionnaires and direct site outreach
- Site profiles that analyze enrollment history, therapeutic experience, and best fit for purpose
- Protocol design and risk discussions
- Rapid generation of site plans based on real-world insights
- Coordinated budget and contract negotiation

A Multi-Center Approach Enhanced by Integration

Our approach to early-phase drug development allows sponsors to combine the scale of a multi-center trial with the consistency and efficiency of a single-provider approach, thanks to our integrated and comprehensive capabilities, including:

- **Comprehensive Bioanalysis:** Expanded capacity for method development, validation, and sample analysis. Custom sample kits ensure consistency across all sites.
- **Seamless Nonclinical-to-Clinical Transition:** Smooth handoffs ensure no loss of knowledge, context, or momentum.
- **Centralized Program Management:** One point of contact drives timelines, communication, and coordination across all sites.
- **Medical Writing and Regulatory Support:** Region-specific documents and submissions keep studies compliant and on track.
- **Adaptive Data Services:** Multiple EDC platforms, real-time data access, and scalability for complex studies.
- **Clinical and Medical Monitoring:** Experienced clinical research assistants and medical monitors ensure GCP compliance, protocol adherence, and patient safety.